A successful safety trial of gentamicin-attenuated Leishmania infantum vaccine in an endemic area in Southeast of Iran.

Abstract

Event Abstract Back to Event A successful safety trial of gentamicin-attenuated Leishmania infantum vaccine in an endemic area in Southeast of Iran. Mohammad J. Namazi1, 2* 1 Sabzevar University of Medical Sciences, immunology, parasitology and microbilogy, Iran 2 University of Glasgow, Center for immunity, infection and inflmmation, United Kingdom Namazi, M. J1. , Daneshvar2, H, and Kamyabi, H2. Leishmania infantum is an obligatory intracellular protozoan and causative of visceral leishmaniasis in human and dogs. Vaccine development in the reservoir host, the domestic dog, is a current research priority. The aim of this study was to conduct safety trial of gentamicin-attenuated L. infantum (L. infantum H-line) in dogs in the endemic area of Southeast Iran. The household dogs were vaccinated subcutaneously with L. infantum H-line. The prospective incidence of natural infection by this vaccine was assessed during a two-year follow up period. The number of animals vaccinated and non-treated control groups was 70 and 50 respectively. The safety of the vaccine on the interruption of the endemic area transmission of the disease was assessed by monitoring the clinical signs and measuring the serum specific anti-Leishmania IgG. No clinical signs of disease including anorexia, apathy, local swelling on injection site, vomiting and diarrhea were developed or observed after the vaccine injection. Therefore, our gentamicin-attenuated L. infantum vaccine induced a significant and strong protective effect against canine leishmaniasis and the consequent transmission to human in the field. Key words: Leishmania infantum, attenuated H-line, vaccine, safety trail 1- Department of Immunology, Parasitology and Microbiology, Faculty of Medicine, Sabzevar University of Medical Sciences, Iran. mjnamazi@gmail.com 2- Department of Immunology, Faculty of Medicine, Kerman University of Medical Sciences, Iran. hamiddaneshvar@gmail.com Keywords: Leishmania infantum, attenuated H-line, Vaccine, safety trail, immune protection Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013. Presentation Type: Abstract Topic: Host-pathogen interactions Citation: Namazi M (2013). A successful safety trial of gentamicin-attenuated Leishmania infantum vaccine in an endemic area in Southeast of Iran. . Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00022 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 08 Mar 2013; Published Online: 22 Aug 2013. * Correspondence: Dr. Mohammad J. Namazi, Sabzevar University of Medical Sciences, immunology, parasitology and microbilogy, Sabzevar, Khorana razavi, 9613873136, Iran, mjnamazi@gmail.com Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Mohammad J. Namazi Google Mohammad J. Namazi Google Scholar Mohammad J. Namazi PubMed Mohammad J. Namazi Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.